구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | WT1 Vaccine |
Overview Company | Sellas Life Sciences Group |
Overview Modality | ANTIBODY |
Overview Target | Ovarian Cancer |
Overview Indication | Ovarian Cancer; Fallopian Tube |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Galinpepimut-S (GPS): an investigational agent for the treatment of acute myeloid leukemia.. Introduction : Acute myeloid leukemia (AML) is a disorder wherein clonal expansion of undifferentiated myeloid precursors results in compromised hematopoiesis and bone marrow failure. Even though numerous AML patients respond to induction chemotherapy, relapse is common and hence new therapeutic approaches… |
Toxicology CRS | Reported |
Clinical Safety signal | Galinpepimut-S (GPS): an investigational agent for the treatment of acute myeloid leukemia.. Introduction : Acute myeloid leukemia (AML) is a disorder wherein clonal expansion of undifferentiated myeloid precursors results in compromised hematopoiesis and bone marrow failure. Even though numerous AML patients respond to induction chemotherapy, relapse is common and hence new therapeutic approaches… |
Clinical Selected reported efficacy | ORR 21.1% |
Clinical Reported ORR | 21.1% |
Clinical Result source | ClinicalTrials.gov NCT03149003 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03149003 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | WT1 Vaccine |
Overview Company | Sellas Life Sciences Group |
Overview Modality | ANTIBODY |
Overview Target | Ovarian Cancer |
Overview Indication | Ovarian Cancer; Fallopian Tube |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Galinpepimut-S (GPS): an investigational agent for the treatment of acute myeloid leukemia.. Introduction : Acute myeloid leukemia (AML) is a disorder wherein clonal expansion of undifferentiated myeloid precursors results in compromised hematopoiesis and bone marrow failure. Even though numerous AML patients respond to induction chemotherapy, relapse is common and hence new therapeutic approaches… |
Toxicology CRS | Reported |
Clinical Safety signal | Galinpepimut-S (GPS): an investigational agent for the treatment of acute myeloid leukemia.. Introduction : Acute myeloid leukemia (AML) is a disorder wherein clonal expansion of undifferentiated myeloid precursors results in compromised hematopoiesis and bone marrow failure. Even though numerous AML patients respond to induction chemotherapy, relapse is common and hence new therapeutic approaches… |
Clinical Selected reported efficacy | ORR 21.1% |
Clinical Reported ORR | 21.1% |
Clinical Result source | ClinicalTrials.gov NCT03149003 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03149003 |
추천 비교
추천 비교